NCT02533258View on ClinicalTrials.gov

Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice

CompletedOBSERVATIONAL
Enrollment

13

Participants

Timeline

Start Date

December 2, 2015

Primary Completion Date

May 12, 2016

Study Completion Date

May 12, 2016

Conditions
Renal Cell Carcinoma
Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02533258 - Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice | Biotech Hunter | Biotech Hunter